KE
CSL Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CSL112 | Acute Coronary Syndrome | Phase 3 |
| CSL312 | Hereditary Angioedema | Phase 3 |
| Eteplirsen | Duchenne Muscular Dystrophy | Commercial |
| Hemgenix (CSL222) | Hemophilia B | Commercial |
| CSL200 | Wilson Disease | Phase 1/2 |
| Albumin Products | Multiple Critical Care Indications | Commercial |
| Immunoglobulin Therapies | Primary Immunodeficiencies | Commercial |
| Factor VIII Products | Hemophilia A | Commercial |
Leadership Team at CSL
PP
Paul Perreault
Chief Executive Officer and Managing Director
JL
Joy Linton
Chief Financial Officer
DB
Dr. Bill Mezzanotte
Chief Medical Officer
SP
Sunny Patel
President, CSL Behring
RS
Raja Singham
President, Seqirus
AN
Andrew Nash
Chief Strategy and Business Development Officer
CC
Christine Carnes
Chief Human Resources Officer
CC
Carolyn Conti
Chief Legal Officer and Company Secretary